Keyphrases
30-day Mortality
13%
Abiraterone
12%
Adjusted Odds Ratio
12%
Antibiotic Exposure
24%
Anticancer Treatment
14%
ARHGEF10
14%
Body Mass Index
20%
Bortezomib
24%
Cancer Treatment
12%
Chemotherapy
18%
Chemotherapy-induced Peripheral Neuropathy
26%
Clinical Outcomes
18%
Comparative Analysis
12%
Consolidation Therapy
12%
COVID-19
100%
COVID-19 Impact
24%
COVID-19 Inpatients
24%
COVID-19 Severity
23%
Disease Genes
24%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
18%
Enzalutamide
12%
Hospitalized Patients
15%
Immune Checkpoint Blockade
12%
Immune Checkpoint Inhibitors
19%
Immunosuppression
13%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
26%
Melanoma
12%
Meta-analysis
12%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
12%
Myocardial Infarction
12%
NCCTG
24%
Non-linear Association
12%
Non-small Cell Lung Cancer Patients
13%
Overall Survival
34%
Paclitaxel-induced Peripheral Neuropathy
24%
Patients with Cancer
53%
Polyneuropathy
13%
Progression-free Survival
17%
Prostate Cancer Patients
12%
Quality Assurance
12%
Registry-based
15%
Retrospective Cohort Study
15%
Risk Factors
18%
Rodents
12%
Sarcoma
12%
Single nucleotide Variant
25%
Small Intestinal Neuroendocrine Tumors
24%
Targeted Therapy
12%
Toxic Polyneuropathy
12%
Venous Thromboembolism
12%
Medicine and Dentistry
Acute Myeloid Leukemia
7%
All Cause Mortality
6%
Antibiotics
24%
Arterial Thromboembolism
12%
Body Mass Index
17%
Breast Cancer
24%
Cancer Therapy
7%
Cancer Treatment
13%
CDKN1B
12%
Cell Line
12%
Chemotherapy-Induced Peripheral Neuropathy
6%
Clinical Trial
5%
Cohort Analysis
34%
Coronavirinae
12%
COVID-19
85%
Cytokine Storm
7%
DeJerine-Sottas Disease
12%
Exome
14%
Health Care
12%
Immune Checkpoint Blockade
12%
Immune Checkpoint Inhibitor
19%
Immunosuppressive Treatment
14%
Immunotherapy
36%
Infection
15%
Logistic Regression Analysis
8%
Lung Cancer
24%
Malignant Neoplasm
68%
Monotherapy
12%
Neoplasm
12%
Neuroendocrine Tumor
24%
Neuroendocrine Tumor Cell Line
9%
Nodular Melanoma
12%
Non Small Cell Lung Cancer
35%
Odds Ratio
9%
Oncology
12%
Overall Survival
33%
Pancreas Islet Cell Tumor
12%
Pembrolizumab
6%
Polyneuropathy
12%
Predictor
12%
Progression Free Survival
15%
Retrospective Cohort Study
14%
Sarcoma
12%
Small Cell Lung Cancer
7%
Small Intestine
12%
Somatic Mutation
12%
Targeted Therapy
6%
Venous Thromboembolism
12%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone
12%
Acute Myeloid Leukemia
9%
Afatinib
12%
All Cause Mortality
7%
Antibiotic Agent
5%
Antibiotics
24%
Bortezomib
12%
Breast Cancer
24%
Chemotherapy
14%
Chemotherapy-Induced Peripheral Neuropathy
9%
Cisplatin
12%
Cohort Study
29%
Coronavirinae
24%
Cyclin Dependent Kinase Inhibitor 1B
12%
Cytokine Storm
7%
Disease
16%
Enzalutamide
12%
Epidermal Growth Factor Receptor
12%
Heart Infarction
12%
Immune Checkpoint Inhibitor
23%
Immunotherapy
30%
Infection
15%
Lung Cancer
24%
Malignant Neoplasm
86%
Monotherapy
12%
Mouse Strain
7%
Neoplasm
12%
Neuroendocrine Tumor
12%
Neurotoxicity
12%
Non Small Cell Lung Cancer
25%
Overall Survival
31%
Pembrolizumab
6%
Progression Free Survival
19%
Prostate Cancer
12%
Side Effect
5%
Venous Thromboembolism
12%